Direction Centrale du Service de Santé des Armées
defense.gouv.frTotal trials
92
Active
18
Phase 3
6
Total enrollment
46,199
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Blood collection | — | — | — | — | — | 5 | |
| Blood sample collection | — | — | — | — | — | 2 | |
| Other biological sample collection | — | — | — | — | — | 1 | |
| Oxygen administration | — | — | — | — | — | 1 | |
| Blood sample | — | — | — | — | — | 1 |
Next readouts
- 2026-08
- 2026-12-31
- 2028-04
Top conditions
- SARS-CoV Infection6
- Covid194
- COVID-193
- Sars-CoV23
- Depression2
- Stress, Psychological2
- Burnout, Caregiver2
- Heat Stroke2
Frequently asked questions about Direction Centrale du Service de Santé des Armées
- How many clinical trials does Direction Centrale du Service de Santé des Armées have on ClinicalTrials.gov?
- Direction Centrale du Service de Santé des Armées is listed as the lead sponsor on 92 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Direction Centrale du Service de Santé des Armées's trials are in Phase 3?
- 6 of Direction Centrale du Service de Santé des Armées's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Direction Centrale du Service de Santé des Armées focus on?
- Direction Centrale du Service de Santé des Armées's most-studied conditions on ClinicalTrials.gov are SARS-CoV Infection, Covid19, COVID-19, Sars-CoV2, Depression.
- When are Direction Centrale du Service de Santé des Armées's next clinical trial readouts?
- Direction Centrale du Service de Santé des Armées has 3 upcoming primary-completion readouts tracked here; the soonest is “Screening for Individual Susceptibility Factors to Immersion Pulmonary Edema”, expected around 2026-08.